Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Drug developer Redx Pharma appoints Iain Ross as new chairman

He has over 35 years’ experience in the life sciences arena
Drug developer Redx Pharma appoints Iain Ross as new chairman
There will be a new face around the boardroom table

Drug developer Redx Pharma Plc (LON:REDX) said Iain Ross will become the company’s chairman effective May 1.

He has over 35 years’ experience and is currently spearheading the turnaround at AIM-listed e-Therapeutics, where he is also chairman.

Ross has boardroom roles at Biomer Technology, Premier Veterinary Group and ASX-quoted Anatara Lifesciences as well as being a director of Aldershot Town Football Club.

Previous appointments included the chairmanship of Silence Therapeutics, chief executive of Allergy Therapeutics and CEO of Quadrant Healthcare.

Welcoming the new chairman on board, RedX boss Neil Murray said: “His extensive experience in the life science sector makes him the ideal candidate to take on this role.

“I am confident that under his stewardship the company will deliver shareholder value as we transition into a clinical-stage research and development company with a focus on cancer, immunology and infection."

CLICK to receive the Proactive newsletter

Ian_55ae0ddd437b7.jpg
Why Invest In Redx Pharma Plc? Read More Here

Register here to be notified of future REDX Company articles
View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
Drugs
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use